Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban via PEG in Fragile AF Patients
NCT06285942Recruiting
- Sponsor
- Azienda Ospedaliero-Universitaria Maggiore della Carità
- Start
- Feb 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of edoxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Maggiore della Carità. Primary endpoint: Anti-Clot Treatment Scale Questionnaire Score at 12 months. Started Feb 2024; status: recruiting.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06285942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285942.